ARTICLE BY LOUIS

• Is Technology The New Science Of Outsourcing?

  5/4/2023

  That’s the abstruse thought with which I left the 2023 CDMO Leadership Awards ceremony in Manhattan. I’ve subsequently tried to sort this out by referring back to a series of interviews I did with CDMO leaders at the event. I think now I can explain this to readers. 

• Gene Therapy Developer Rocket Pharma Aims High

  3/1/2023

  “From our first patient until now, all our manufactured drug product that has treated patients has been produced in partnership with CDMOs,” says Gaurav Shah, M.D., cofounder and CEO of Rocket Pharma.

• A Real Celebration Of The Best CDMOs

  3/1/2023

  This annual issue presenting our readers with the best-of-the-best CDMOs is once again accompanied by a live celebration in Manhattan. However, in two ways the 2023 Awards differ from those of the past.

• A More Balanced And Stable Future With CDMOs

  12/1/2022

  Two Industry Experts talk about where they see the outsourcing industry going in the near future.

• Safe At Home With Generics

  7/13/2022

  “I have not wanted to go to India or China for most of my API needs, and to the extent possible I do not want to go there for formulations either,” is part of a surprising sentiment from a long-tenured generics outsourcing professional.  

• The Hardest Job In All BioPharma: The CTO

  6/1/2022

  CTO roles have expanded, deepened, and pressurized – particularly at drug sponsors reliant on outsourcing development and manufacturing capabilities. Now CTOs are actively seeking ways to improve their leadership skills so they can better handle the transforming environment.

• We’ve Moved Forward

  3/1/2022

  In addition to our annual CMO Leadership awards, what you’ll read in these pages is the importance of continuing to advance the knowledge, best practices, and strategies of outsourcing we’ve been covering now for nearly a decade in this issue.

• Outsourcing From A To ZZ Biotech

  3/1/2022

  Kent Pryor, CEO of ZZ Biotech, explains how he’s approached his single-handed “CEO As Outsourcer” role and provides advice to professionals of all positions in any biopharma organization.

• Defending Your Supply Chains From “Foreign Suppliers”

  1/13/2022

  In “defense” of the integrity of your (offshore and onshore) drug development and manufacturing outsourcing, and during this year 3 CE (Covid Era): Considering suppliers as separate and somewhat removed entities – putting them at a distance – might be what it takes to subsequently bring you even closer to reliable partnerships. 

• These Professionals Are Creating Our Outsourcing Future

  12/1/2021

  While asking executives their views on the future of outsourcing drug development and manufacturing, I arrived at an epiphany of sorts: They are the future of biopharma outsourcing.